Characteristics of Familial Lung Cancer in Yunnan-Guizhou Plateau of China

Xiaojie Ding¹, Ying Chen¹,², Jiapeng Yang², Guangjian Li², Huatao Niu², Rui He², Jie Zhao² and Huanqi Ning²

¹ Key Laboratory of Lung Cancer Research of Kunming Medical University, Kunming, China, ² Yunnan Cancer Hospital and The Third Affiliated Hospital of Kunming Medical University & Yunnan Cancer Center, Kunming, China

Background: Lung cancer has inherited susceptibility and show familial aggregation, the characteristics of familial lung cancer exhibit population heterogeneity. Despite previous studies, familial lung cancer in China’s Yunnan-Guizhou plateau remains understudied.

Methods: Between 2015 and 2017, 1,023 lung cancer patients (residents of Yunnan-Guizhou plateau) were enrolled with no limitation on other parameters, 152 subjects had familial lung cancer. Clinicopathologic parameters were analyzed and compared, 4,754 lung cancer patients from NCI-GDC were used to represent a general population.

Results: Familial lung cancer (FLC) subjects showed unique characters: early-onset; increased rate of female, adenocarcinoma, stage IV and other cancer history; unbalance in anatomic sites; all ruling out significant difference in smoking status. Unbalanced distribution of co-existing diseases or symptoms was also discovered. FLC patients were more likely to develop benign lesions (polyps, nodules, cysts) early in life, especially early-growth of multiple pulmonary nodules at higher frequency. Typical diseases with family history like diabetes and hypertension were also increased in FLC population. Compared to GDC data, our subject population was younger: the age peak of our FLC group was in 50–59; our sporadic group had an age peak around 60; while GDC patients’ age peak was in 60–69. Importantly, the biggest difference happened in age 40–49: our FLC group and sporadic group had 3 times and 2 times higher ratio than GDC population, respectively. Moreover, the age peaks of our FLC males and FLC females were both in 50–59; while our sporadic females had the age peak in 50–59, much earlier than sporadic males (around 60–69); reflecting gender-specific or age-specific characters in our subject population.

Conclusions: Familial lung cancer in China’s Yunnan-Guizhou plateau showed unique clinicopathologic characters, differences were found in gender, age, histologic type, TNM stage and co-existing diseases or symptoms. Identification of hereditary factors which lead to increased lung cancer risk will be a challenge of both scientific and clinical significance.

Keywords: familial lung cancer, cancer susceptibility, Yunnan-Guizhou plateau of China, clinicopathologic characteristics, family history
INTRODUCTION

Lung cancer is often cited as a malignancy largely determined by environmental factors (1). However, Epidemiological surveys suggest that lung cancer show familial aggregation after proper adjustments for tobacco smoking and other environmental factors, indicating inherited genetic susceptibility is a typical feature of familial lung cancer (1–4).

Familial lung cancer (FLC) exhibit special features when compared with the sporadic counterpart, previous findings show similarity and diversity in different FLC populations, depending on the subjects’ source. Even majoriy of them find an increased lung cancer risk in FLC population, the fold change vary from 1.3 ∼3.5 (2–7). In addition, some support certain ethnic groups are affected more by inherited lung cancer susceptibility (6, 7); others find first-degree female relatives have a higher risk than first-degree male relatives (4, 8); and another suggests there seems to be a particular link between FLC and EGFR mutation in tumors of affected family members (3). In summary, genetic predisposition to lung cancer may be inherited with complex patterns in populations, and there can be unique characteristics within each population or subprocessution.

Lung cancer is a disease induced by interaction between genetic and environmental factors, and hypoxia is a typical feature of tumor microenvironment. Previous findings (9–11) suggest genetic adaptations to life at high altitude could potentially have different effects on human diseases in which hypoxia is a feature. Located in southwest China, Yunnan-Guizhou plateau has an average elevation of 2 kilometers (range: 1.5 ∼ 4 kilometers). Populations living in high altitude regions (terrestrial elevation >2 kilometers) exhibit unique circulatory, respiratory, hematological and immune adaptations (12–15); beside phenotypes, the highlanders also vary in their genetic background (9, 10, 12, 16). Many features of high land residents have been characterized physiologically and pathologically (17, 18), especially cardiovascular disease and respiratory disease, in which lower oxygen of high elevation is considered as one key factor.

So it would be reasonable to predict: lung cancer, especially familial lung cancer of highland residents may harbor unique characters, when compared with general population. Current study is to investigate and characterize the clinicopathologic features of familial and sporadic lung cancer in China’s Yunnan-Guizhou plateau, moreover provide insight into complex genetic susceptibility of lung cancer.

MATERIALS AND METHODS

Patients

This trial was designed as a single-center real-world observational study. The lung cancer patients who enrolled in Department of Thoracic Surgery I of Yunnan Cancer Hospital from Jan. 2015 to Jan. 2017 were recruited. In order to investigate the characters of highland population with and without familial lung cancer, patients met the following criteria were selected: (1) The subject can be permanent native of Yunnan-Guizhou plateau; (2) If the subject’s ancestor migrated from other provinces, the family has lived on this plateau for at least 3 generations. In total, 1023 lung cancer patients were enrolled with no limitation on other parameters. (3) Subject with familial lung cancer is defined as individual has three or more first-degree relatives affected by lung cancer. There were 152 patients who were classified as having familial lung cancer. All the information were based on self-report and confirmed by personal medical records.

Clinicopathologic data were documented in hospital cooperated databank (https://www.linkdoc.com), including age, gender, blood type, histologic type, family history etc. The TNM stage was reviewed according to the 8th edition of The International Association for the Study of Lung Cancer (IASLC) staging system. The majority of patients enrolled had adenocarcinoma (AD), squamous cell carcinoma (SCC) and small cell lung cancer (SCLC). Other co-existing diseases or symptoms were also documented, including: diabetes, hypertension, gallstone, gallbladder polyp, hepatic cysts, hepatic hemangioma, fatty liver, thyroid nodule, thyroid cysts, ovarian cysts, uterine myoma, renal cysts, renal stone and multiple pulmonary nodules. The study was approved by the Ethical Committees of Yunnan Cancer Hospital. All patients provided informed consent.

Compare With Other Population

We first compared familial and sporadic lung cancer patients in our region; since non-plateau area data were not available, we chose GDC lung cancer data to represent a general population for further comparison. National Cancer Institute Genomic Data Commons (NCI-GDC) provide representative data on human cancers, including subjects of different ethnic groups. Since data on patients’ living altitude was not available, subjects could come from all possible elevations. Basic information like gender, age and lung cancer histologic type were obtained from NCI-GDC (https://portal.gdc.cancer.gov). In total, 4754 lung cancer patients (male: 2401, female: 2349, unreported: 4) were included (Table S2). The data were compared with present work.

Statistical Analysis

Chi-square test and Fischer’s exact test were used to analyze the association of clinic-pathological parameters with familial lung cancer. SPSS 17.0 was used (SPSS Institute, Chicago, IL, USA). Statistical significance was set at $p < 0.05$ (two-sided p-value).

RESULTS

Clinic-Pathological Features of Familial and Sporadic Lung Cancer in China’s Yunnan-Guizhou Plateau

In total 1023 subjects were enrolled in the study, 152 were identified as familial lung cancer patients. The characters were

Abbreviations: FLC, familial lung cancer; AD, Adenocarcinoma; SCC, squamous cell carcinoma; SCLC, small cell lung cancer.
**TABLE 1** | Clinical pathological characteristics of 1,023 lung cancer patients.

| Variables                          | Total   | Family history of lung cancer | P value<sup>a</sup> |
|-----------------------------------|---------|-------------------------------|---------------------|
|                                  |         | Positive | Negative                  |                     |
| Total number of patients          | 1,023   | 152 (14.86%) | 871 (85.14%)            | 0.29                |
| Gender                            |         |           |                           |                     |
| Male                              | 671     | 94 (61.84%) | 577 (66.25%)             |                     |
| Female                            | 352     | 58 (38.16%) | 294 (33.75%)             |                     |
| Average age: 58 years (range 27–85) | 822    | 112 (73.68%) | 710 (81.52%)             | 0.03                |
| ≥50 years                         |         |           |                           |                     |
|                                    | 822     | 112 (73.68%) | 710 (81.52%)             |                     |
| <50 years                         | 201     | 40 (26.32%) | 161 (18.48%)             |                     |
| Blood type                        |         |           |                           | 0.39                |
| A                                 | 344     | 43 (28.29%) | 301 (34.56%)             |                     |
| B                                 | 307     | 46 (30.26%) | 261 (29.97%)             |                     |
| AB                                | 103     | 16 (10.53%) | 87 (9.99%)               |                     |
| O                                 | 269     | 47 (30.92%) | 222 (25.49%)             |                     |
| Smoking history                   |         |           |                           | 0.53                |
| Yes (Current or Ex-smoker)        | 481     | 75 (49.34%) | 406 (46.61%)             |                     |
| Never                             | 542     | 77 (50.66%) | 465 (53.39%)             |                     |
| Anatomy site                      |         |           |                           | 0.02<sup>b</sup>    |
| Left lung                         | 463     | 82 (53.96%) | 381 (43.74%)             |                     |
| Right lung                        | 550     | 68 (44.74%) | 482 (55.34%)             |                     |
| Bilateral lung                    | 7       | 1 (0.66%)  | 6 (0.69%)                |                     |
| Main bronchus                     | 3       | 1 (0.66%)  | 2 (0.23%)                |                     |
| Histology type                    |         |           |                           | 0.13                |
| Adenocarcinoma                    | 640     | 108 (71.05%) | 532 (61.08%)            |                     |
| Squamous cell carcinoma           | 266     | 30 (19.74%) | 236 (27.10%)             |                     |
| Small cell lung cancer            | 95      | 11 (7.24%)  | 84 (9.64%)               |                     |
| Others                            | 22      | 3 (1.97%)  | 19 (2.18%)               |                     |
| Stage                             |         |           |                           | 0.26                |
| I                                 | 251     | 39 (25.66%) | 212 (24.34%)             |                     |
| II                                | 111     | 14 (9.21%)  | 97 (11.14%)              |                     |
| III                               | 304     | 37 (24.34%) | 267 (30.65%)             |                     |
| IV                                | 357     | 62 (40.79%) | 295 (33.87%)             |                     |
| Distant organ metastasis          |         |           |                           | 0.12                |
| Present                           | 227     | 41 (26.97%) | 186 (21.35%)             |                     |
| Absent                            | 796     | 111 (73.03%) | 685 (78.65%)             |                     |

<sup>a</sup>For categorical variables, using Chi-square test or Fisher's exact test, when there is a cell frequency &lt; 5.

<sup>b</sup>p-value calculated for left/right lung only, other sites are not included.

listed in Table 1 and Table S1. The familial lung cancer (FLC) group included 94 (61.8%) males and 58 (38.2%) females, with an average age of 56 (range 28 - 83). There were 108 (71.1%) adenocarcinoma (AD), 30 (19.7%) squamous cell carcinoma (SCC), and 11 (7.2%) small cell lung cancer (SCLC). Most patients (62 cases, 40.8%) had stage IV disease, followed by stage I (39 cases, 25.7%) and stage III (37 cases, 24.3%). 14 patients (9.2%) had stage II disease. For 871 sporadic lung cancer patients, average age was 58 (range 27–85). There were 532 (61.1%) AD cases, 236 (27.1%) SCC cases and 84 (9.6%) SCLC cases; majority had stage IV disease (295 cases, 33.9%), followed by stage III (267 cases, 30.7%), and 311 (35.5%) patients were in stage I or II.

**Familial Lung Cancer Subjects of Highland Population: Early Onset; Increased Frequency of: Female, Adenocarcinoma and Stage IV; Unbalance in Anatomic Sites**

Highland FLC population was compared with the sporadic counterpart, importantly no significant difference was found in smoking status. Considering age at diagnosis, there were more individuals under age 50 in FLC group, and more older patients (≧ 63 years) in sporadic group (Table 1, Figure 1A). Interestingly, FLC group showed two peaks (46 vs. 58 years), sporadic group also had double peaks (53 vs. 63 years), but both were later than FLC counterpart (Figure 1A), it could suggest
other potential risk factors genetically or environmentally. Each age section included more than 100 subjects with most sections around 150, reflecting nearly even distribution of patients in each age group; the number of FLC females started to decrease after age 65, while FLC males dropped slower in older age (Figure 1B).

Even not significant, the ratios of: female, AD histology, stage IV and other organ metastasis were all higher in FLC group (Figures 1C–E). Interestingly, significant difference was found on anatomic sites, FLC patients had cancer on left lung more frequent (54.7 vs. 44.2%, \( P = 0.02 \)). In total, ratios of stage T4, N3, M1, and IV all increased in FLC subjects, potentially reflecting...
FIGURE 2 | (A) Patients stage-age distribution of FLC and sporadic individuals. In FLC group, more males were found in stage IIIA and IV, and females were accumulated in stage IV. For sporadic group, males were enriched in stage IIIA and IV, but stage IA, IB, IIA, IIB all had much more males than their FLC counterpart, while many females were in stage IV, high number of females were also found in stage IA and IB. (B) Difference in co-existing diseases or symptoms. In total, 15 had higher frequency in FLC group (including: multiple pulmonary nodules, distant organ metastasis, other cancer history, diabetes, hypertension, thyroid cysts, thyroid cancer, hepatic cysts, fatty liver, hepatic hemangioma, renal cysts, gallbladder polyp, gall stone, uterine myoma, uterine cysts) and only 4 (prostatic hyperplasia, thyroid nodule, renal stone, ovarian cysts) were lower in FLC patients.
FIGURE 3 | Age and gender distribution of co-existing diseases or symptoms. Divided by age, 7 showed the major increase under age 50 for FLC population (including: AD histology, multiple pulmonary nodules, distant organ metastasis, hepatic cysts, hepatic hemangioma, renal cysts, gallbladder polyp) (A1,A4,A7,A8,A10–12); fatty liver had major increase under age 55 in FLC group (A9). 3 had no apparent age distribution variation between familial and sporadic (Continued)
higher cancer aggressiveness. Further divided by histologic type (AD, SCC, SCLC), stage IV and M1 were found increased in all subgroups with FLC, while stage T4 and N3 raised only in AD and SCC with FLC (Figure 1E).

Evaluated by gender, age, and stage together, for most stages, the patient age ranged from 30 years to around 80 years, only stage IIA had less subjects. Majority of patients were in stage IIIA to IV. In FLC group, more males were found in stage IIIA and IV, compared with males in other stages, while females were accumulated in stage IV. For sporadic subjects, males were also enriched in stage IIIA and IV, but stage IA, IB, IIA, IIB all had much more males than their FLC counterpart, while many females were in stage IV, high number of females were also found in stage IA and IB (Figure 2A).

Unbalanced Distribution of Co-existing Diseases Between Familial and Sporadic Lung Cancer in Highland Population

We also investigated other co-existing diseases or symptoms in our subjects (Table S1). In total, 15 had higher frequency in FLC group (including: multiple pulmonary nodules, distant organ metastasis, other cancer history, diabetes, hypertension, thyroid cysts, thyroid cancer, hepatic cysts, fatty liver, hepatic hemangioma, renal cysts, gallbladder polyp, gall stone, uterine myoma, uterine cysts) and only 4 (prostatic hyperplasia, thyroid cysts also had major increase under age 55 for FLC group, but thyroid nodule had the peak around age 55–64 (A13,A14). Divided by gender, for histologic type, no apparent gender differences were found between FLC and sporadic group (B1); for TNM stage, there were more females in T2, T4, N3, M1, and stage IV in FLC group (B2–5); when considering co-existing diseases, 6 showed more females with FLC (including: diabetes, thyroid cancer, hepatic cysts, hepatic hemangioma, fatty liver, renal stone); while more FLC males were found with gallbladder polyp, gall stone and multiple pulmonary nodules; only diabetes, thyroid cancer and gallbladder polyp were statistically significant (B6).

Comparison Between Highland Lung Cancer With Other Lung Cancer Population

Present study was compared with data from NCI-GDC (https://portal.gdc.cancer.gov). In total 4754 lung cancer patients (male: 2401, female: 2349, unreported: 4) were included (Table S2). Gender and lung cancer histology had relatively even distribution in GDC patients, but in present study, female patients were clearly dominated by AD histology (Figure 4A,B). Because record of lung cancer family history is not available in GDC data, and according to most references, early-onset is one crucial feature of familial lung cancer (1, 2, 4, 6), furthermore, present study found the major age difference between our familial and sporadic group was around age 50 (Figure 1A), so we divided the GDC lung cancer population into 0–49 and 50–100 years for further comparison.

Compared with present study, divided GDC patients had similar gender and lung cancer histology distribution. In GDC population, 0–49 years subjects had statistically higher female ratio, similar to FLC patients of present work (Figure 4C); moreover, younger GDC patients also showed increased AD histology for male, female and in total (Figures 4E,G,I).

Age was the most interesting. In total, GDC subjects developed lung cancer at much older age (peak: 60–69) than not only the FLC group (peak: 50–59), but also the sporadic group (peak ≤ 60) of present study (Figure 4D), indicating the overall early-onset of our subject population. Importantly, the biggest difference happened in 40–49 age section, the ratio of our FLC patients was 3 times higher than GDC population, while our sporadic group had nearly 2 times higher ratio than GDC subjects. In males, age distribution of the 3 groups was similar to that of total population, and age 40–49 still held the biggest variation, except the main age peak of our sporadic males moved to higher than 60 years (Figure 4F). In females, the age peak was still in 60–69 for GDC population, while the age curve of our familial and sporadic females almost overlapped (peak: 50–59), the only ratio difference was in age 40–49: FLC females was a little higher than the sporadic part, but both were more than 2 times higher in ratio than GDC females (Figure 4H). All together, the results suggest: our subject population may harbor gender-specific or age-specific characters.

A brief comparison on overall survival and mutation spectrum was carried for GDC population (Figure S1). No apparent survival difference was found between 0–49 and 50–100 age groups, but there were small variations in mutation for different age and gender groups. Since present study
FIGURE 4 | Comparison between highland lung cancer with NCI-GDC lung cancer population. (A) Gender and lung cancer histology distribution in GDC patients. (B) Gender and lung cancer histology distribution in present study; In GDC population, 0–49 years subjects had statistically higher female ratio, similar to FLC patients of present work (C). Younger GDC patients also showed increased AD histology for male, female and in total (E,G,I). (D) In total, GDC subjects developed lung cancer at much older age (peak: 60–69) than both the FLC group (peak: 50–59) and the sporadic group (peak ≤ 60) of present study; (F) In males, age distribution of the 3 groups was similar to that of total population, the main peak of our sporadic males moved to higher than 60 years. (H) In females, the age curves of our familial and sporadic females almost overlapped with each other, the only difference was at age 40–49.
didn’t include survival and mutation data, according to previous reports (19–21), there could be potential mutation differences between familial and sporadic lung cancer in highland population.

**DISCUSSION**

Relatives of cancer patients are at an increased risk for the same cancer and also other cancers, among the 27 most common cancers, significant risk ratios were found for pancreatic (2.31), lung (1.69), kidney (1.98), nervous system (1.79), and thyroid cancers (3.28) (2, 22). Two meta-analysis performed on more than 60 studies reported an approximately 2-fold increase associated with family history of lung cancer (23, 24). One investigation conducted by the International Lung Cancer Consortium (ILCCO) in 2012 including 24,000 cases and 23,000 controls, reported a significant 1.5-fold increase in risk due to family history after adjustment for environmental confounders (6); this study also confirmed a higher risk in African-Americans (2.09-fold risk) than Caucasians (1.53-fold risk). Importantly, inherited risks can be further amplified by environmental carcinogen exposure (7).

Younger age at diagnosis is the typical character of familial cancers (25–27). Present study found similar but more complex results (Figure 1A). Although FLC and sporadic group had a small average age gap (56 vs. 58), FLC group included significantly more patients under age 50, and both showed double peaks (FLC: 46 vs. 58; sporadic: 53 vs. 63). This could indicate contribution from multiple factors or existing of subgroups in each population. Firstly, it may reflect different carcinogen exposure at various levels; secondly, since family history is not equal to susceptibility, there can be susceptible individuals in sporadic group and non-susceptible individuals in FLC group; both may cause age peak to split. Noticeably, when compared with GDC data, our subject population showed apparent overall early-onset, it may be explained by higher carcinogen exposure or genetic background variation at population level.

FLC patients tended to have more AD histology, other cancer history, distant organ metastasis and stage IV cases, the latter two are indicator of increased cancer aggressiveness. Studies on young lung cancer patients also supported high AD ratio, prevalence of female and diagnosed in advanced stages (25, 26, 28, 29). Other interesting results included: the age curve of our FLC and sporadic males separated clearly, while age curve of our FLC and sporadic females almost overlapped with each other (Figures 4F,H). One study observed higher risks for female relatives of female proband vs. male relatives of male proband (30); another also supported first-degree female relatives seemed to have a higher risk than first-degree male relatives (4); the third one found female gender and FLC were the most important predictor of lung cancer (8); all reflecting the possibly gender-specific or age-specific characters in different FLC populations.

Regarding to co-existing diseases or symptoms (Table S1, Figure 3), there were also gender-specific or age-specific variations between FLC and sporadic group. FLC patients were more likely to develop benign lesions (polyps, nodules, cysts) early in life. Especially high ratio and early-growth of multiple pulmonary nodules, indicating unhealthy of the lung even before cancer developed. Diabetes and hypertension are typical diseases with family history, and their frequency also increased in our FLC group compared with sporadic counterpart, with diabetes statistically higher in females.

**CONCLUSION**

Present study revealed the clinicopathologic characteristics of familial and sporadic lung cancer in highland population of China, discovered complex differences in gender, age, histologic type, TNM stage and co-existing diseases or symptoms. Future task is to identify hereditary factors which influence lung cancer risk, and also highlight the significance of lung cancer susceptibility screen in our population.

**AUTHOR CONTRIBUTIONS**

YC and XD conception and design. JY, HNiu, and GL data acquisition, data analysis, and interpretation. YC, XD, JY, RH, JZ, and HNin drafting the article and revising it for important intellectual content.

**FUNDING**

This work was supported by National Natural Science Foundation of China (No: 81702274); Internal Organization Research Projects of Yunnan Cancer Hospital (No: 2017NS198); Yunnan Applied Basic Research Projects-Union Foundation [No: 2017FE468 (-159), 2015FB069, 2017FE467 (-0187), 2017FE468 (-214),2018-JY-Y-085]; Doctor Research Foundation of Yunnan Cancer Hospital (No: BSKY201705). Scientific Research Foundation Projects of Yunnan Provincial Department of Education (No: 2017ZZX197).

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2018.00637/full#supplementary-material

**Figure S1** | Comparison on overall survival and mutation spectrum in GDC population. (A) overall survival (age:0–49); (B) overall survival (age: 50–100); (C) Mutations: male (age: 0–49); (D) Mutations: female (age: 0–49); (E) Mutations: male (age: 50–100); (F) Mutations: female (age: 50–100).

**Table S1** | Other co-existing diseases or symptoms in 1,023 lung cancer patients.

**Table S2** | Clinicopathologic characteristics of 4,754 lung cancer patients from NCI-GDC.
REFERENCES

1. Musolf AM, Simpson CL, de Andrade M, Mandal D, Gaba C, Yang P, et al. Familial lung cancer: a brief history from the earliest work to the most recent studies. *Genes* (2017) 8:E36. doi: 10.3390/genes810036

2. Frank C, Sundquist J, Yu H, Hemminki A, Hemminki K. Concordant and discordant familial cancer. Familial risks, proportions and population impact. *Int J Cancer* (2017) 140:1510–6. doi: 10.1002/ijc.30583

3. Gaughan EM, Cryer SK, Yeap BY, Jackman DM, Costa DB. Family history of lung cancer in never smokers with non-small-cell lung cancer and its association with tumors harboring EGFR mutations. *Lung Cancer* (2013) 79:193–7. doi: 10.1016/j.lungcan.2012.12.002

4. Lin H, Huang Y-S, Yan H-h, Yang X-N, Zhong W-Z, Ye H-W, et al. A family history of cancer and lung cancer risk in never-smokers. A clinic-based case-control study. *Lung Cancer* (2015) 89:94–8. doi: 10.1016/j.lungcan.2015.05.017

5. Isla D, Felip E, Vinolas N, Provencio M, Majem M, Artal A, et al. Lung cancer in women with a family history of cancer. The Spanish Female-specific Database WORLD7. *Anticancer Res.* (2016) 36:6647–53. doi: 10.21873/anticancer.11273

6. Coté ML, Liu M, Bonassi S, Neri M, Schwartz AG, Christiani DC, et al. Increased risk of lung cancer in individuals with a family history of the disease. A pooled analysis from the international lung cancer consortium. *Eur J Cancer* (2012) 48:1957–68. doi: 10.1016/j.ejca.2012.01.038

7. Coté ML, Kardia SLR, Wenzlaff AS, Ruckdeschel JC, Schwartz AG. Risk of lung cancer among white and black relatives of individuals with early-onset lung cancer. *JAMA* (2005) 293:3036–42. doi: 10.1001/jama.293.24.3036

8. Lin K-F, Wu H-F, Huang W-C, Tang P-L, Wu M-T, Wu F-Z. Propensity score analysis of lung cancer risk in a population with high prevalence of non-smoking related lung cancer. *BMC Pulm Med.* (2017) 17:120. doi: 10.1186/s12890-017-0465-8

9. Bigham A, Bauchet M, Pinto D, Mao X, Akey JM, Mei R, et al. Identifying signatures of natural selection in Tibetan and Andean populations using dense genome scan data. *PLoS Genet.* (2010) 6:e1001116. doi: 10.1371/journal.pgen.1001116

10. Bigham AW, Lee FS. Human high-altitude adaptation: forward genetics meets the HIF pathway. *Genes Dev.* (2014) 28:2189–204. doi: 10.1101/gad.250167.114

11. Horvost JF, Katwica AO, Laner V, West JA, Hennis PJ, Levet DZH, et al. Metabolic basis to Sherpa altitude adaptation. *Proc Natl Acad Sci USA.* (2017) 114:E382–7. doi: 10.1073/pnas.1700527114

12. Huerta-Sánchez E, Jin X, Asan BZ, Peter BM, Vinckenbosch N, et al. Adaptation to Tibetans caused by introgression of Denisovan-like DNA. *Nature* (2014) 512:194–7. doi: 10.1038/nature13408

13. Biainha, Berntsen S, Andreason LB, Stigum H, Ouzhuluolu, Nafstad P, et al. Exercise capacity and selected physiological factors by ancestry and residential altitude: cross-sectional studies of 9-10-year-old children in Tibet. *High Alt Med Biol.* (2014) 15:162–9. doi: 10.1089/ham.2013.1084

14. Eisen S, Pealing L, Aldridge RW, Siedner MJ, Necochea A, Leybll E, et al. Effects of ascent to high altitude on human antimycobacterial immunity. *PLoS ONE* (2013) 8:e74220. doi: 10.1371/journal.pone.0074220

15. Simonson TS, Wei G, Wagner HE, Wuren T, Qin G, Yan M, et al. Low haemoglobin concentration in Tibetan males is associated with greater high-altitude exercise capacity. *J Physiol.* (2015) 593:3207–18. doi: 10.1111/jjp27058

16. Tomar A, Malhotra S, Sarkar S. Polymorphism profiling of nine high altitude relevant candidate gene loci in acclimatized sojourners and adapted natives. *BMC Genet.* (2015) 16:112. doi: 10.1186/s12863-015-0268-y

17. Negi PC, Marwaha R, Asotra S, Kandoria A, Ganju N, Sharma R, et al. Prevalence of high altitude pulmonary hypertension among the natives of Spiti Valley—a high altitude region in Himachal Pradesh, India. *High Alt Med Biol.* (2014) 15:504–10. doi: 10.1089/ham.2013.1112

18. Okumiyi K, Sakamoto R, Ishimoto Y, Kimura Y, Fukutomi E, Ishikawa M, et al. Glucose intolerance associated with hypoxia in people living at high altitudes in the Tibetan highland. *BMJ Open* (2016) 6:e009728. doi: 10.1136/bmjopen-2015-009728

19. Yang IA, Holloway JW, Fong KM. Genetic susceptibility to lung cancer and co-morbidities. *J Thorac Dis.* (2013) 5 (Suppl. 5):S545–62. doi: 10.3978/j.issn.2072-1439.2013.08.06

20. Timofeeva MN, Hung RJ, Rafnar T, Christiani DC, Field JK, Bickeboller H, et al. Influence of common genetic variation on lung cancer risk. Meta-analysis of 14,900 cases and 29,485 controls. *Hum Mol Genet.* (2012) 21:4980–95. doi: 10.1093/hmg/ddz334

21. Liu Y, Kheradmand F, Davis CF, Scheurer ME, Wheeler D, Tsavachidis S, et al. Focused analysis of exome sequencing data for rare germline mutations in familial and sporadic lung cancer. *J Thorac Oncol.* (2016) 11:52–61. doi: 10.109/j.jtoh.2015.09.015

22. Dai J, Shen W, Wen W, Chang J, Wang T, Chen H, et al. Estimation of heritability for nine common cancers using data from genome-wide association studies in Chinese population. *Int J Cancer* (2017) 140:329–36. doi: 10.1002/ijc.30447

23. Gu J, Hua F, Zhong D, Chen J, Liu H, Zhou Q. Systematic review of the relationship between family history of lung cancer and lung cancer risk. *Zhongguo Fei Ai Za Zhi.* (2010) 13:224–9. doi: 10.3779/jissn.1009-3419.2010.03.07

24. Matakidou A, Eisen T, Houlston RS. Systematic review of the relationship between family history and lung cancer risk. *Br J Cancer* (2005) 93:825–33. doi: 10.1038/sj.bjc.6602769

25. Hsu C-L, Chen K-Y, Shih J-Y, Ho C-C, Yang C-H, Yu C-J, et al. Advanced non-small cell lung cancer in patients aged 45 years or younger. Outcomes and prognostic factors. *BMC Cancer* (2012) 12:241. doi: 10.1186/1471-2407-12-241

26. Kozieł J, Kaczmarczyk G, Porębska I, Smygim-Milanowska K, Golecki M. Lung cancer in patients under the age of 40 years. *Contemp Oncol.* (2016) 12:413–5. doi: 10.5114/wo.2012.31770

27. Li J, Yang E, Li X, Zhang M, Fu R, Yin X, Wang J. Characteristics, survival, and risk factors of Chinese young lung cancer patients the experience from two institutions. *Oncotarget* (2017) 8:89236–44. doi: 10.18632/oncotarget.19183

28. Li Y, Wang Y, Li JL, Hao XZ, Hu XS, Wang HY. Trend analysis and clinicopathological characteristics of 198 young patients with advanced lung adenocarcinoma. *Zhonghua Zhong Liu Za Zhi* (2016) 38:750–5. doi: 10.3760/cma.j.issn.0253-3766.2016.10.007

29. Radzikowska E, Roszkowski K, Głaz P. Lung cancer in patients under 50 years old. *J Thorac Dis.* (2017) 9(Suppl. 5):S454–62. doi: 10.3978/j.issn.2072-1439.2017.01.01

30. Goldgar DE, Easton DF, Cannon-Albright LA, Skolnick MH. Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. *J Natl Cancer Inst.* (1994) 86:1600–8.

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 Ding, Chen, Yang, Li, Niu, He, Zhao and Ning. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.